AcelRx Pharmaceuticals Inc.

0.1800-0.0194-9.73%Vol 909.30K1Y Perf -85.45%
Jun 24th, 2022 16:00 DELAYED
BID0.1707 ASK0.2100
Open0.2035 Previous Close0.1994
Pre-Market- After-Market0.21
 - -  0.03 14.44%
Target Price
4.00 
Analyst Rating
Moderate Buy 2.00
Potential %
2.12K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.44 
Earnings Rating
Strong Buy
Market Cap26.48M 
Earnings Date
15th Aug 2022
Alpha-0.02 Standard Deviation0.24
Beta0.71 

Today's Price Range

0.18000.2100

52W Range

0.16001.55

5 Year PE Ratio Range

-2.00-3.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-15.09%
1 Month
-21.77%
3 Months
-42.86%
6 Months
-67.86%
1 Year
-85.45%
3 Years
-91.78%
5 Years
-91.63%
10 Years
-94.19%

TickerPriceChg.Chg.%
ACRX0.1800-0.0194-9.73
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.06-0.060.00
Q04 2021-0.06-0.060.00
Q03 2021-0.07-0.070.00
Q02 2021-0.08-0.080.00
Q01 2021-0.08-0.080.00
Q04 2020-0.12-0.1016.67
Q03 2020-0.07-0.10-42.86
Q02 2020-0.14-0.0842.86
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.0516.67Positive
9/2022 QR-0.0516.67Positive
12/2022 FY-0.220.00-
12/2023 FY-0.1313.33Positive
Next Report Date15th Aug 2022
Estimated EPS Next Report-0.05
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume909.30K
Shares Outstanding147.12K
Shares Float145.46M
Trades Count1.71K
Dollar Volume179.42K
Avg. Volume1.22M
Avg. Weekly Volume860.18K
Avg. Monthly Volume1.49M
Avg. Quarterly Volume1.31M

AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) stock closed at 0.18 per share at the end of the most recent trading day (a -9.73% change compared to the prior day closing price) with a volume of 909.30K shares and market capitalization of 26.48M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 54 people. AcelRx Pharmaceuticals Inc. CEO is Vincent J. Angotti.

The one-year performance of AcelRx Pharmaceuticals Inc. stock is -85.45%, while year-to-date (YTD) performance is -67.87%. ACRX stock has a five-year performance of -91.63%. Its 52-week range is between 0.16 and 1.55, which gives ACRX stock a 52-week price range ratio of 1.44%

AcelRx Pharmaceuticals Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 71.81, a price-to-sale (PS) ratio of 11.35, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -43.71%, a ROC of -% and a ROE of 106.17%. The company’s profit margin is -%, its EBITDA margin is -1 122.60%, and its revenue ttm is $2.75 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from AcelRx Pharmaceuticals Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. AcelRx Pharmaceuticals Inc.’s next earnings report date is 15th Aug 2022.

The consensus rating of Wall Street analysts for AcelRx Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $4, which is +2 122.22% compared to the current price. The earnings rating for AcelRx Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AcelRx Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AcelRx Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.18, ATR14 : 0.03, CCI20 : -110.87, Chaikin Money Flow : -0.33, MACD : -0.01, Money Flow Index : 25.42, ROC : -15.53, RSI : 38.31, STOCH (14,3) : 0.00, STOCH RSI : 0.04, UO : 30.51, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AcelRx Pharmaceuticals Inc. in the last 12-months were: Vincent J. Angotti (Buy at a value of $10 333)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

AcelRx Pharmaceuticals Inc.

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system) SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for the reduction of moderate-to-severe acute pain in medically supervised settings.

CEO: Vincent J. Angotti

Telephone: +1 650 216-3500

Address: 351 Galveston Drive, Redwood City 94063, CA, US

Number of employees: 54

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

63%38%

Bearish Bullish

61%39%

News

Stocktwits